Moderna : Initial data offer hope – capital increase of $ 1.34bn
>Positive interim data - Moderna yesterday afternoon published interim phase I data for its SARS-COV2 vaccine candidate. Although these are interim data with very few patients, we can at this stage highlight the quality of these data which will clearly have to be confirmed going forward. Briefly, we note the design of the trial, the primary endpoint being the safety of the vaccination schedule followed by initial signs of efficacy (immunogenicity and neutralising anti...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.